Stacker on MSN

5 sales sequences that drive higher response rates

Apollo reports five effective sales sequences for higher response rates, emphasizing personalization and timing to boost ...
Seeking Alpha

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway SCLC is aggressive and ...
MarketWatch

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...
The American Journal of Managed Care

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Zongertinib shows a 71% response rate and 12.4 months median progression-free survival in HER2-mutated NSCLC, with minimal adverse events. Patient-reported outcomes indicate rapid improvement in ...
radaronline

Increase Response Rates by Applying the Right Cold Emailing Practices

Cold emailing is a trusted marketing and selling tool. However, older techniques need to evolve over time to produce better results to align with recent trends. If you continue relying on outdated ...
Nasdaq

Iovance Biotherapeutics Reports 61% Response Rate for Amtagvi® in Third-Line Melanoma Patients

Iovance Biotherapeutics announced promising results from a real-world study of its commercially available Amtagvi® (lifileucel) for treating advanced melanoma in patients previously treated with ...
Seeking Alpha

Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without ...
National Academies of Sciences%2c Engineering%2c and Medicine

Nonresponse in Social Science Surveys: A Research Agenda

In a paper initially prepared for the planning meeting for this review, Peytchev (2013) observes that drawing “unbiased inference from probability-based surveys relies on the collection of data from ...